C/EBP transcription factors in human squamous cell carcinoma: Selective changes in expression of isoforms correlate with the neoplastic state

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Anand, Sanjay ^a   Ebner, John ^a   Warren, Christine B ^a   Raam, Manu S ^a   Piliang, Melissa ^a   Billings, Steven D ^a   Maytin, Edward V ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; PROTEIN P30; PROTEIN P40; RNA ISOFORM;

ARTICLE; BINDING AFFINITY; BINDING SITE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; GEL MOBILITY SHIFT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SKIN BIOPSY; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR DIFFERENTIATION; UPREGULATION; WESTERN BLOTTING; ALTERNATIVE RNA SPLICING; BIOPSY; CANCER STAGING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SKIN TUMOR; TUMOR CELL LINE;

ALTERNATIVE SPLICING; BIOPSY; CARCINOMA, SQUAMOUS CELL; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; PHOSPHORYLATION; RNA ISOFORMS; SKIN NEOPLASMS;

EID: 84912143436     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112073     Document Type: Article

References (59)

1. Birkenmeier EH, Gwynn B, Howard S, Jerry J, Gordon JI, et al. (1989) Tissuespecific expression, developmental regulation, and genetic mapping of the gene encoding CCAAT/enhancer binding protein. Genes Dev 3: 1146-1156.
2. Johnson PF, Landschulz WH, Graves BJ, McKnight SL (1987) Identification of a rat liver nuclear protein that binds to the enhancer core element of three animal viruses. Genes Dev 1: 133-146.
3. Cao Z, Umek RM, McKnight SL (1991) Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev 5: 1538-1552.
4. Johnson PF (2005) Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci 118: 2545-2555.
5. Nerlov C (2007) The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol 17: 318-324.
6. Zahnow CA (2009) CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med 11: e12.
7. Koschmieder S, Halmos B, Levantini E, Tenen DG (2009) Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 27: 619-628.
8. Pabst T, Mueller BU (2009) Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clin Cancer Res 15: 5303-5307.
9. Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, et al. (2005) Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin Cancer Res 11: 3184-3190.
10. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, et al. (2002) Downregulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res 62: 528-534.
11. Xu L, Hui L, Wang S, Gong J, Jin Y, et al. (2001) Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res 61: 3176-3181.
12. Bennett KL, Hackanson B, Smith LT, Morrison CD, Lang JC, et al. (2007) Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res 67: 4657-4664.
13. Takai N, Kawamata N, Walsh CS, Gery S, Desmond JC, et al. (2005) Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. Mol Cancer Res 3: 261-269.
14. Thompson EA, Zhu S, Hall JR, House JS, Ranjan R, et al. (2011) C/EBPalpha expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBPalpha confers susceptibility to UVB-induced skin squamous cell carcinomas. J Invest Dermatol 131: 1339-1346.
15. Milde-Langosch K, Loning T, Bamberger AM (2003) Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cellcycle regulatory proteins. Breast Cancer Res Treat 79: 175-185.
16. Raught B, Gingras AC, James A, Medina D, Sonenberg N, et al. (1996) Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein beta isoform and up-regulation of the eukaryotic translation initiation factor 2alpha are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res 56: 4382-4386.
17. Gomis RR, Alarcon C, Nadal C, Van Poznak C, Massague J (2006) C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10: 203-214.
18. Sundfeldt K, Ivarsson K, Carlsson M, Enerback S, Janson PO, et al. (1999) The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. Br J Cancer 79: 1240-1248.
19. Oya M, Horiguchi A, Mizuno R, Marumo K, Murai M (2003) Increased activation of CCAAT/enhancer binding protein-beta correlates with the invasiveness of renal cell carcinoma. Clin Cancer Res 9: 1021-1027.
20. Rask K, Thorn M, Ponten F, Kraaz W, Sundfeldt K, et al. (2000) Increased expression of the transcription factors CCAAT-enhancer binding protein-beta (C/EBBeta) and C/EBzeta (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer 86: 337-343.
21. Sankpal NV, Moskaluk CA, Hampton GM, Powell SM (2006) Overexpression of CEBPbeta correlates with decreased TFF1 in gastric cancer. Oncogene 25: 643-649.
22. Balamurugan K, Sterneck E (2013) The many faces of C/EBPdelta and their relevance for inflammation and cancer. Int J Biol Sci 9: 917-933.
23. Verbeek W, Wachter M, Lekstrom-Himes J, Koeffler HP (2001) C/EBPepsilon 2/2 mice: increased rate of myeloid proliferation and apoptosis. Leukemia 15: 103-111.
24. Korabiowska M, Cordon-Cardo C, Betke H, Schlott T, Kotthaus M, et al. (2002) GADD153 is an independent prognostic factor in melanoma: immunohistochemical and molecular genetic analysis. Histol Histopathol 17: 805-811.
25. Calkhoven CF, Muller C, Leutz A (2000) Translational control of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev 14: 1920-1932.
26. Descombes P, Schibler U (1991) A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 67: 569-579.
27. Dearth LR, Hutt J, Sattler A, Gigliotti A, DeWille J (2001) Expression and function of CCAAT/enhancer binding proteinbeta (C/EBPbeta) LAP and LIP isoforms in mouse mammary gland, tumors and cultured mammary epithelial cells. J Cell Biochem 82: 357-370.
28. Zahnow CA, Younes P, Laucirica R, Rosen JM (1997) Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J Natl Cancer Inst 89: 1887-1891.
29. Eaton EM, Hanlon M, Bundy L, Sealy L (2001) Characterization of C/EBPbeta isoforms in normal versus neoplastic mammary epithelial cells. J Cell Physiol 189: 91-105.
30. Bundy LM, Sealy L (2003) CCAAT/enhancer binding protein beta (C/EBPbeta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture. Oncogene 22: 869-883.
31. Bundy L, Wells S, Sealy L (2005) C/EBPbeta-2 confers EGF-independent growth and disrupts the normal acinar architecture of human mammary epithelial cells. Mol Cancer 4: 43.
32. Loomis KD, Zhu S, Yoon K, Johnson PF, Smart RC (2007) Genetic ablation of CCAAT/enhancer binding protein alpha in epidermis reveals its role in suppression of epithelial tumorigenesis. Cancer Res 67: 6768-6776.
33. Shim M, Powers KL, Ewing SJ, Zhu S, Smart RC (2005) Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation. Cancer Res 65: 861-867.
34. Oh HS, Smart RC (1998) Expression of CCAAT/enhancer binding proteins (C/EBP) is associated with squamous differentiation in epidermis and isolated primary keratinocytes and is altered in skin neoplasms. J Invest Dermatol 110: 939-945.
35. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC (2002) CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci U S A 99: 207-212.
36. Yoon K, Zhu S, Ewing SJ, Smart RC (2007) Decreased survival of C/EBP betadeficient keratinocytes is due to aberrant regulation of p53 levels and function. Oncogene 26: 360-367.
37. Sterneck E, Zhu S, Ramirez A, Jorcano JL, Smart RC (2006) Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis. Oncogene 25: 1272-1276.
38. Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, et al. (2010) The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J 29: 4106-4117.
39. Pawar SA, Shao L, Chang J, Wang W, Pathak R, et al. (2014) C/EBPdelta deficiency sensitizes mice to ionizing radiation-induced hematopoietic and intestinal injury. PLoS One 9: e94967.
40. Rheinwald JG, Beckett MA (1981) Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res 41: 1657-1663.
41. Zhang W, Vaccariello MA, Wang Y, Alt-Holland A, Fusenig NE, et al. (2005) Escape from microenvironmental control and progression of intraepithelial neoplasia. Int J Cancer 116: 885-893.
42. Anand S, Honari G, Hasan T, Elson P, Maytin EV (2009) Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res 15: 3333-3343.
43. Sinha AK, Anand S, Ortel BJ, Chang Y, Mai Z, et al. (2006) Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Br J Cancer 95: 485-495.
44. Schreiber E, Matthias P, Muller MM, Schaffner W (1989) Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17: 6419.
45. Anand S, Hasan T, Maytin EV (2013) Mechanism of differentiation-enhanced photodynamic therapy for cancer: upregulation of coproporphyrinogen oxidase by C/EBP transcription factors. Mol Cancer Ther 12: 1638-1650.
46. Taniguchi M, Hashimoto M, Hori N, Sato K (2005) CCAAT/enhancer binding protein-beta (C/EBP-beta), a pivotal regulator of the TATA-less promoter in the rat catalase gene. FEBS Lett 579: 5785-5790.
47. Maytin EV, Habener JF (1998) Transcription factors C/EBP alpha, C/EBP beta, and CHOP (Gadd153) expressed during the differentiation program of keratinocytes in vitro and in vivo. J Invest Dermatol 110: 238-246.
48. Bull JJ, Muller-Rover S, Chronnell CM, Paus R, Philpott MP, et al. (2002) Contrasting expression patterns of CCAAT/enhancer-binding protein transcription factors in the hair follicle and at different stages of the hair growth cycle. J Invest Dermatol 118: 17-24.
49. Yoon K, Smart RC (2004) C/EBPalpha is a DNA damage-inducible p53-regulated mediator of the G1 checkpoint in keratinocytes. Mol Cell Biol 24: 10650-10660.
50. Minner F, Poumay Y (2009) Candidate housekeeping genes require evaluation before their selection for studies of human epidermal keratinocytes. J Invest Dermatol 129: 770-773.
51. Ridky TW (2007) Nonmelanoma skin cancer. J Am Acad Dermatol 57: 484-501.
52. Chen C, Dudenhausen EE, Pan YX, Zhong C, Kilberg MS (2004) Human CCAAT/enhancer-binding protein beta gene expression is activated by endoplasmic reticulum stress through an unfolded protein response element downstream of the protein coding sequence. J Biol Chem 279: 27948-27956.
53. Thiaville MM, Dudenhausen EE, Zhong C, Pan YX, Kilberg MS (2008) Deprivation of protein or amino acid induces C/EBPbeta synthesis and binding to amino acid response elements, but its action is not an absolute requirement for enhanced transcription. Biochem J 410: 473-484.
54. Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, et al. (1993) Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A 90: 2207-2211.
55. Atwood AA, Jerrell R, Sealy L (2011) Negative regulation of C/EBPbeta1 by sumoylation in breast cancer cells. PLoS One 6: e25205.
56. Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, et al. (2003) A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114: 323-334.
57. Zahnow CA, Cardiff RD, Laucirica R, Medina D, Rosen JM (2001) A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation. Cancer Res 61: 261-269.
58. Kowenz-Leutz E, Leutz A (1999) A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes. Mol Cell 4: 735-743.
59. Schuster MB, Porse BT (2006) C/EBPalpha: a tumour suppressor in multiple tissues? Biochim Biophys Acta 1766: 88-103.